Enrollment has been completed in a phase 2 clinical trial of NCX 4251, a treatment candidate for acute exacerbations of blepharitis, Nicox announced in a press release.
The objective of the multicenter, dose-escalating trial is to select the dose of NCX 4251 — an ophthalmic suspension of fluticasone propionate nanocrystals — to advance into a phase 2b clinical trial, the release said.
“NCX 4251 is an innovative product candidate, both through the choice of active ingredient and form of application, which targets the unmet need in acute exacerbations of blepharitis,”
Uncategorized